ModernaMRNA
Market Cap: $28B
About: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Employees: 5,600
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
63% more funds holding in top 10
Funds holding in top 10: 8 [Q1] → 13 (+5) [Q2]
60% more first-time investments, than exits
New positions opened: 123 | Existing positions closed: 77
10% more capital invested
Capital invested by funds: $28.3B [Q1] → $31.1B (+$2.89B) [Q2]
5% more funds holding
Funds holding: 873 [Q1] → 919 (+46) [Q2]
9% more repeat investments, than reductions
Existing positions increased: 325 | Existing positions reduced: 298
0.77% less ownership
Funds ownership: 69.18% [Q1] → 68.41% (-0.77%) [Q2]
16% less call options, than puts
Call options by funds: $1.56B | Put options by funds: $1.86B
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
11 analyst ratings
HSBC Yifeng Liu 100% 1-year accuracy 1 / 1 met price target | 13%upside $82 | Hold Upgraded | 28 Aug 2024 |
JP Morgan Jessica Fye 62% 1-year accuracy 23 / 37 met price target | 21%upside $88 | Neutral Maintained | 15 Aug 2024 |
Deutsche Bank Emmanuel Papadakis 33% 1-year accuracy 1 / 3 met price target | 10%upside $80 | Hold Upgraded | 6 Aug 2024 |
RBC Capital Luca Issi 33% 1-year accuracy 16 / 48 met price target | 23%upside $90 | Sector Perform Downgraded | 5 Aug 2024 |
RBC Capital Luca Issi 33% 1-year accuracy 16 / 48 met price target | 71%upside $125 | Outperform Maintained | 2 Aug 2024 |
Financial journalist opinion
Based on 256 articles about MRNA published over the past 30 days